-transparent.png){kind=logo}
A novel method for the selective depletion of lymphocyte subpopulations has been developed. Conjugates of glucose oxidase (GOx) and phospholipase-C (PL-C) coupled to a monoclonal mouse anti-rat IgG (MAR) were shown to be selectively cytotoxic for targeted lymphocyte subsets in the presence of various rat monoclonal antibodies directed toward murine cell surface antigens. The ability of both conjugates to bind specifically to rat monoclonal antibodies was demonstrated by flow cytometry. The PL-C-MAR conjugate was more stable than the GOx-MAR conjugate. The PL-C conjugate, in conjunction with primary rat anti-mouse monoclonal antibodies, produced selective killing of T or B cells as detected by a loss of proliferative capacity in response to mitogens and by specific cell depletion demonstrated by flow cytometry. Normal mouse serum protected against the cytotoxicity of free enzymes but had no protective effect on enzyme conjugates. Because the substrates of these enzymes are abundant in vivo and serum did not interfere with their cytotoxicity, these enzyme-antibody conjugates may be valuable for selective lymphocyte depletion in vivo.
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
December 2001,
Advanced drug delivery reviews,
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
September 1994,
Methods and findings in experimental and clinical pharmacology,
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
June 1994,
Trends in biotechnology,
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
January 1987,
La Ricerca in clinica e in laboratorio,
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
August 1981,
Proceedings of the National Academy of Sciences of the United States of America,
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
February 1985,
Journal of clinical & laboratory immunology,
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
November 2020,
Biomaterials,
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
January 1989,
Progress in clinical and biological research,
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
October 1994,
Anti-cancer drug design,
R B Lal, and
E M Brown, and
B E Seligmann, and
L J Edison, and
T M Chused
September 1983,
Presse medicale (Paris, France : 1983),
